Detalhe da pesquisa
1.
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell;
185(12): 2116-2131.e18, 2022 06 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35662412
2.
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Cell;
185(14): 2422-2433.e13, 2022 07 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35772405
3.
Human antibody C10 neutralizes by diminishing Zika but enhancing dengue virus dynamics.
Cell;
184(25): 6067-6080.e13, 2021 12 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34852238
4.
The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses.
Cell;
184(25): 6052-6066.e18, 2021 12 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34852239
5.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell;
184(9): 2348-2361.e6, 2021 04 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33730597
6.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell;
184(11): 2939-2954.e9, 2021 05 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33852911
7.
Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
Nat Immunol;
21(3): 354, 2020 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32001822
8.
A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection.
Nat Immunol;
20(10): 1291-1298, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31477918
9.
The immune response against flaviviruses.
Nat Immunol;
19(11): 1189-1198, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30333606
10.
Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.
Nat Immunol;
19(11): 1248-1256, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30323338
11.
Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
Nat Immunol;
18(11): 1261-1269, 2017 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28945244
12.
Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response.
Nat Immunol;
18(11): 1228-1237, 2017 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28945243
13.
Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
Nat Immunol;
17(9): 1102-8, 2016 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27339099
14.
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
Nat Immunol;
16(2): 170-177, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25501631
15.
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Lancet;
399(10324): 521-529, 2022 02 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35074136
16.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet;
399(10319): 36-49, 2022 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34883053
17.
Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
Nat Immunol;
16(7): 785, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26086146
18.
Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
Nat Immunol;
16(5): 544, 2015 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25898199
19.
Structural basis of potent Zika-dengue virus antibody cross-neutralization.
Nature;
536(7614): 48-53, 2016 08 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27338953
20.
Recognition determinants of broadly neutralizing human antibodies against dengue viruses.
Nature;
520(7545): 109-13, 2015 Apr 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25581790